 InVivo Therapeutics Holdings Corp. Nasdaq: NVIV today announced the closing of its previously announced public offering of 2,545,455 shares of common stock or pre-funded warrants to purchase common stock in lieu thereof, together with warrants to purchase up to 2,545,455 shares of common stock at a combined effective price to the public of 2.75 per share or pre-funded warrant and associated warrant. The gross proceeds from this offering were approximately 7.0 million, before deducting the placement agent fees and estimated offering expenses payable by InVivo Therapeutics. 